WuXi STA Breaks Ground in New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Del., August 16, 2022 /PRNewswire/ — WuXi STA, a leading contract research, development and manufacturing organization (CRDMO), is pleased to announce the grand opening of its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021this site will be WuXi STA’s second installation in United Statesproviding increased capacity and greater flexibility to meet the needs of customers in the United States and around the world.

The WuXi STA Middletown site is located in the Middletown business center at 1091 Industrial Drive, and the new state-of-the-art facility will create approximately 500 full-time jobs by 2026. Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labeling, storage and distribution services for clinical trial materials and commercial drug products.

WuXi STA has 12 locations across the United States, Europe and Asia that offer a range of services and meet or exceed all regulatory standards. With three other drug manufacturing sites in Couvet (Swiss), Wuxi City (China) and Shanghai (China), this new facility will further strengthen the company’s global drug manufacturing capacity and capabilities.

“The biopharmaceutical industry is part of from Delaware DNA,” said Delaware Governor John Carney. “Over the next five years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of from Delaware fastest growing communities, bringing with them good jobs and economic growth. This campus is only possible thanks to from Delaware a world-class innovative workforce. Thanks to WuXi STA, Middletown Mayor Kenny Branner and everyone who made this project possible.”

“The First State continues to be a premier destination for companies looking to innovate and grow,” said Senator Tom Carper. “This investment from WuXi STA helps position Delaware as a continuing global leader in biopharmaceuticals, further cementing the manufacturing power of one of our fastest growing communities. from Delaware The workforce is ready to help build the future of our life-saving pharmaceuticals. This state-of-the-art campus will create good jobs and help strengthen our supply chains here at home. »

“This biopharmaceutical facility is one of the largest private sector investments ever made in the Middletown Region,” said Senator Chris Coon. “I am delighted with WuXi STA’s decision to choose Middletown for one of their new manufacturing facilities. This is not just the largest private sector investment in from Middletown history – it’s a defining moment that will bring many more well-paying jobs to Delaware and further cement the first state as a world leader in biopharmaceutical research and manufacturing. Thank you all for Middletown at Dover at Washington who have helped us get here, whether by continuing to invest in NIIMBL, improving our education system from kindergarten to our universities, or ensuring that Delaware workers have the skills manufacturers like WuXi AppTec are looking for. »

“As the first state, Delaware has always had a spirit of innovation – constantly seeking new opportunities and businesses that will strengthen our economy and our state as a whole,” said representing Lisa Blunt Rochester. “Today’s grand opening of the WuXi STA pharmaceutical manufacturing plant represents another step in that spirit of innovation – bringing well-paying jobs to Middletown and strengthening communities through Delaware. The state-of-the-art facility will bring 500 full-time jobs over the next few years, increasing our state’s workforce and allowing us to manufacture more goods domestically, improving our economic competitiveness on the global stage. »

“We look forward to our partnership with WuXi STA, as today’s grand opening marks the start of their new home in Middletown, Delaware. WuXi STA will join our bustling industrial area, just steps from Clarios, Datwyler, Amazon and Breakthru Beverage, just some of the companies that have invested in Middletown. When asked by WuXi STA about our business-friendly attitude, these companies expressed their wholehearted support for the way we do business and we couldn’t be more excited that WuXi STA wants to join them, and the city of Middletownin our journey together,” said Middletown Mayor Ken Branner. Branner added that he was grateful for the governor’s support. John Carney and the Delaware Prosperity Partnership.

“I would like to thank our federal, state and local partners in Delaware for their continued support in creating this site,” said dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA. “WuXi STA continues to increase our capabilities and capabilities to better serve our customers through a more robust and reliable supply chain. With our integrated platform of research, development and contract manufacturing organization ( CRDMO) and our proven quality system, we look forward to working with our customers to bring their innovative therapies to market quickly to save lives and improve healthcare for patients.”

The WuXi STA Middletown facility is expected to begin operations in 2025.

About WuXi STA

WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry. life, with global operations. As a premier Contract Research, Development and Manufacturing Organization (CRDMO), WuXi STA provides its global partners with efficient, flexible and high-quality solutions for Integrated Chemistry, Manufacturing and Controls (CMC), preclinical uses to commercial uses, including development and manufacturing. small molecules, oligonucleotides, peptides and various complex chemical conjugates. For more information, please visit: http://www.STApharma.com

About WuXi AppTec

As a global company with operations across Asia, Europeand North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discovery and deliver breakthrough treatments to patients. With its unique business models, WuXi AppTec’s end-to-end integrated services include CRDMO (Contract Research, Development and Manufacturing Organization) drug chemistry, biology discovery, preclinical testing and clinical research services, therapeutics cell and gene CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advanced healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2021 and its self-service platform empowers more than 5,850 employees in more than 30 countries to improve the health of those in need – and realize the vision that ” every medicine can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com

Media Contact:

Davy Wu

[email protected]

SOURCE WuXi AppTec